Global Ertapenem Injection Market Size By Type (1g/Vial, Others), By Application (Adult, Pediatric), By Region, And Segment Forecasts, 2023 to 2032

The Global Ertapenem Injection Market was valued at USD 1.1 billion in 2023 and is projected to reach USD 1.9 billion by 2031, growing at a CAGR of 6.8% during the forecast period from 2023 to 2031. The market is driven by the increasing prevalence of complicated infections, rising resistance to other antibiotic classes, and growing adoption of injectable carbapenems for treating multidrug-resistant bacterial infections. Ertapenem, a once-daily broad-spectrum carbapenem antibiotic, is increasingly favored for its effectiveness against community-acquired infections and its lower potential for hospital-acquired resistance development.

Drivers

Rising Prevalence of Complicated Infections

The growing incidence of complicated urinary tract infections (cUTIs), intra-abdominal infections (cIAIs), and skin and soft tissue infections, particularly in hospitalized patients, is boosting demand for Ertapenem injections. Its broad-spectrum activity and once-daily dosing make it ideal for both inpatient and outpatient settings.

Antibiotic Resistance Crisis

The global increase in resistance to cephalosporins, fluoroquinolones, and aminoglycosides has pushed clinicians to adopt carbapenems, including Ertapenem, as part of empirical therapy for serious infections.

Clinical Preference for Once-Daily Dosing

Ertapenem's once-daily intravenous administration offers greater convenience for both healthcare providers and patients, especially in outpatient parenteral antibiotic therapy (OPAT), reducing hospitalization time and associated costs.

Restraints

Patent Expiry and Generic Competition

The expiration of branded patents has resulted in the proliferation of generic versions, driving down prices and margins for established players in the market.

Limited Activity Against Certain Pathogens

Ertapenem lacks activity against non-fermenters like Pseudomonas aeruginosa and Acinetobacter baumannii, limiting its use in hospital-acquired infections where these pathogens are prevalent.

Opportunity

Expanding Healthcare Infrastructure in Emerging Markets

The rapid improvement of hospital infrastructure and healthcare accessibility in Asia-Pacific, Latin America, and parts of Africa presents untapped potential for injectable antibiotics, including Ertapenem.

Increase in Outpatient Parenteral Antibiotic Therapy (OPAT) Programs

The global shift toward cost-effective, home-based infection management is driving demand for antibiotics like Ertapenem, which are ideal for OPAT settings due to their convenient dosing and effectiveness.

Market by System Type Insights

Based on system type, Lyophilized Powder for Injection dominated the market in 2023, driven by its superior shelf-life and ease of storage and transport. It is widely used in hospital pharmacies and OPAT programs due to its flexibility in dosing and preparation. However, the Premixed Injection Solution segment is expected to witness faster growth owing to increasing demand for ready-to-use formats in busy clinical settings.

Market by End-use Insights

Hospitals remained the leading end-user segment in 2023, accounting for over 50% of the global market share. The high burden of complicated infections requiring intravenous antibiotics in inpatient settings supports this dominance. Meanwhile, Home Healthcare Services are rapidly growing, supported by the global shift to OPAT and chronic disease management at home.

Market by Regional Insights

North America led the global market in 2023, driven by strong healthcare infrastructure, high awareness about antimicrobial resistance, and widespread OPAT adoption. However, Asia-Pacific is expected to experience the highest CAGR during the forecast period due to expanding healthcare access, rising infection rates, and increasing adoption of generic carbapenems in countries like China and India.

Competitive Scenario

Key market players include Merck & Co., Inc. (INVANZ®), Pfizer Inc., Sandoz (a Novartis division), Fresenius Kabi, Mylan N.V., and Hikma Pharmaceuticals. These companies focus on generic competition, cost-effective manufacturing, and expanding into emerging markets. Strategic developments include:

2023: Pfizer launched a co-marketing initiative in Latin America to increase access to its injectable antibiotic portfolio, including Ertapenem.

2024: Hikma received FDA approval for its generic Ertapenem 1g injection, further intensifying competition in the U.S. market.

2025: Merck announced a collaborative study on Ertapenem resistance mechanisms in partnership with academic research centers in Europe.

Scope of Work – Global Ertapenem Injection Market

Key Market Developments

June 2023: Sandoz expanded its manufacturing plant in India to meet rising global demand for injectable antibiotics, including Ertapenem.

October 2024: Fresenius Kabi launched an extended shelf-life premixed Ertapenem solution for European markets.

March 2025: Merck announced a strategic licensing deal with a Chinese pharmaceutical firm to distribute Ertapenem across Asia-Pacific.

FAQs

What is the current market size of the Global Ertapenem Injection Market?

The market was valued at USD 1.1 billion in 2023.

What is the major growth driver of the Global Ertapenem Injection Market?

The major growth driver is the rising prevalence of complicated bacterial infections and antibiotic resistance.

Which is the largest region during the forecast period in the Global Ertapenem Injection Market?

North America held the largest market share in 2023, but Asia-Pacific is expected to grow the fastest.

Which segment accounted for the largest market share in Global Ertapenem Injection Market?

The Hospital segment accounted for the largest share in 2023 due to high demand in inpatient infection treatment.

Who are the key market players in the Global Ertapenem Injection Market?

Major players include Merck & Co., Pfizer Inc., Sandoz, Fresenius Kabi, Mylan N.V., and Hikma Pharmaceuticals.